Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression‐free survival (PFS) and the overall response rate (ORR) vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma. All patients were previously...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Sunami, Kazutaka, Matsue, Kosei, Suzuki, Kenshi, Takezako, Naoki, Shinagawa, Atsushi, Sakurai, Sanae, Tamakoshi, Hiromi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293071/
https://ncbi.nlm.nih.gov/pubmed/32297407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14415
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados